FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004281409> ?p ?o ?g. }

• W2004281409 abstract "To the Editor: Parkinsonism is a neurologic syndrome that manifests as any combination of 6 cardinal features: tremor at rest, rigidity, bradykinesia/hypokinesia, flexed posture, loss of postural reflexes, and the freezing phenomenon.1 At least 2 of these features, with at least 1 being either tremor at rest or bradykinesia, must be present for a definitive diagnosis of parkinsonism.1 The biochemical abnormality in parkinsonism is reduced dopaminergic neurotransmission in the basal ganglia.1In 1954, Steck2 first described neuroleptic-induced parkinsonism in patients taking chlorpromazine. This observation was confirmed by Gade and Heinrich3 in 1955. The prevalence of neuroleptic-induced parkinsonism is difficult to ascertain because of heterogenous patient populations, variable drug regimens, and other factors that make this distinction extremely difficult. In most cases, however, it is second only to Parkinson's disease as the most common cause of parkinsonism.4,5,6 Various medications such as neuroleptics, selective serotonin reuptake inhibitors, lithium, valproic acid, calcium channel blockers, antiarrhythmics, procholinergics, chemotherapeutics, amphotericin B, estrogen, and others have been implicated.4 To our knowledge, we are reporting the first published case of aripiprazole-induced parkinsonism.Case report. A 12-year-old white boy presented to the emergency department in 2010 with chief complaints of excessive drooling, generalized slowing of body movements, and difficulty in walking with stiffness in arms and legs for 3 days. His psychiatric history was significant for posttraumatic stress disorder (PTSD; nightmares, flashbacks, numbing, avoidance, and sexually acting-out behavior) due to physical and sexual abuse, attention-deficit/hyperactivity disorder (ADHD; hyperactivity, impulsivity, and inattention), oppositional defiant disorder (ODD), and mood disorder not otherwise specified (longstanding history of mood dysregulation, mood swings, and excessive irritability). On mental status examination, he described his mood as “sad.” His affect was blunted, his speech was limited to short response, and he denied having audiovisual hallucinations. He was not delirious. On physical examination, he was found to have bradykinesia, lip smacking, flexed posture, and cogwheel rigidity. There was no past history of illicit substance or alcohol abuse. There was no family history of movement disorders.His outpatient medications included lisdexamfetamine 70 mg orally every morning and guanfacine 1 mg orally every morning. Within 3 days of initiation of benztropine 1 mg orally twice daily and aripiprazole 5 mg/d orally, he developed classic parkinsonian symptoms, ie, bradykinesia, cogwheel rigidity, and flexed posture. After emergency department stabilization, he was admitted to the inpatient psychiatry unit with an additional diagnosis of neuroleptic-induced parkinsonism. Findings from his routine blood work including complete blood cell count with differential, comprehensive metabolic profile, and drug screen as well as noncontrast head computed tomography scan were within normal limits. All medications were stopped except benztropine 1 mg orally twice daily, and amantadine 100 mg orally twice daily was given, which led to symptom resolution within 72 hours. After release from the hospital, he was rechallenged with an antipsychotic, quetiapine extended release (XR) 50 mg orally every evening, with reemergence of parkinsonian symptoms. Quetiapine XR was discontinued, with dramatic resolution of parkinsonian symptoms.A PubMed search for the years 1954 to 2010 with the keywords antipsychotics, aripiprazole, parkinsonism, and children was performed, and a Google Scholar search incorporating the same keywords and range of years was also conducted. To our knowledge, only 2 casereports of drug-induced parkinsonism in children7,8 have been published.Neuroleptic-induced parkinsonism results from a diminution in dopamine activity.9 This can be induced by depletion of dopamine in presynaptic stores (eg, during reserpine treatment), dopamine-blocking agents (eg, antipsychotics), and the atypical calcium-blocking agent cinnarizine.9 Dopamine-2 blockade in nigrostriatal dopamine system results in parkinsonian symptoms in patients who are taking antipsychotics.10 This effect is frequent with typical antipsychotics, being strong D2 blockers, compared to atypical antipsychotics, which are relatively weak D2 blockers.11 Absence of tremor and reversibility are typical of drug-induced parkinsonism rather than Parkinson's disease.12This syndrome usually subsides with dose reduction or medication cessation.9 As such reduction or cessation is not always possible, alternative strategies include switching from a high-potency D2 blocking agent (eg, fluphenazine) to a lower-potency first-generation antipsychotic or second-generation antipsychotic agent (eg, quetiapine). According to the literature, aripiprazole, a partial D2 agonist, may also decrease the risk of acute extrapyramidal symptoms.9 Adjunctive anticholinergic agents, eg, benztropine or dopamine agonists such as amantadine, are effective agents to alleviate extrapyramidal symptoms (EPS).9Physicians should look for the symptoms of parkinsonism and movement disorders in children who are on treatment with antipsychotics, either typical or atypical. Incidence of EPS appears to be greater for typical antipsychotics. Among atypical antipsychotics, hierarchy of EPS risk is risperidone > olanzapine = ziprasidone = aripiprazole > quetiapine > clozapine.10,13 If challenged by a neuroleptic again, patients may have reemergence of parkinsonian symptoms." @default.
• W2004281409 created "2016-06-24" @default.
• W2004281409 creator A5004347713 @default.
• W2004281409 creator A5018959426 @default.
• W2004281409 creator A5023492932 @default.
• W2004281409 creator A5023990808 @default.
• W2004281409 creator A5079980511 @default.
• W2004281409 date "2011-06-23" @default.
• W2004281409 modified "2023-09-23" @default.
• W2004281409 title "Aripiprazole-Induced Parkinsonism in a Child" @default.
• W2004281409 cites W1513749687 @default.
• W2004281409 cites W155569344 @default.
• W2004281409 cites W189994894 @default.
• W2004281409 cites W1990732390 @default.
• W2004281409 cites W2088857180 @default.
• W2004281409 cites W2139779072 @default.
• W2004281409 cites W2410846152 @default.
• W2004281409 cites W2418422303 @default.
• W2004281409 cites W60662833 @default.
• W2004281409 doi "https://doi.org/10.4088/pcc.10l01081" @default.
• W2004281409 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3184558" @default.
• W2004281409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21977366" @default.
• W2004281409 hasPublicationYear "2011" @default.
• W2004281409 type Work @default.
• W2004281409 sameAs 2004281409 @default.
• W2004281409 citedByCount "2" @default.
• W2004281409 countsByYear W20042814092020 @default.
• W2004281409 countsByYear W20042814092023 @default.
• W2004281409 crossrefType "journal-article" @default.
• W2004281409 hasAuthorship W2004281409A5004347713 @default.
• W2004281409 hasAuthorship W2004281409A5018959426 @default.
• W2004281409 hasAuthorship W2004281409A5023492932 @default.
• W2004281409 hasAuthorship W2004281409A5023990808 @default.
• W2004281409 hasAuthorship W2004281409A5079980511 @default.
• W2004281409 hasBestOaLocation W20042814092 @default.
• W2004281409 hasConcept C118552586 @default.
• W2004281409 hasConcept C126322002 @default.
• W2004281409 hasConcept C15744967 @default.
• W2004281409 hasConcept C2776412080 @default.
• W2004281409 hasConcept C2776525014 @default.
• W2004281409 hasConcept C2779134260 @default.
• W2004281409 hasConcept C2780211496 @default.
• W2004281409 hasConcept C71924100 @default.
• W2004281409 hasConceptScore W2004281409C118552586 @default.
• W2004281409 hasConceptScore W2004281409C126322002 @default.
• W2004281409 hasConceptScore W2004281409C15744967 @default.
• W2004281409 hasConceptScore W2004281409C2776412080 @default.
• W2004281409 hasConceptScore W2004281409C2776525014 @default.
• W2004281409 hasConceptScore W2004281409C2779134260 @default.
• W2004281409 hasConceptScore W2004281409C2780211496 @default.
• W2004281409 hasConceptScore W2004281409C71924100 @default.
• W2004281409 hasLocation W20042814091 @default.
• W2004281409 hasLocation W20042814092 @default.
• W2004281409 hasLocation W20042814093 @default.
• W2004281409 hasLocation W20042814094 @default.
• W2004281409 hasOpenAccess W2004281409 @default.
• W2004281409 hasPrimaryLocation W20042814091 @default.
• W2004281409 hasRelatedWork W2104622314 @default.
• W2004281409 hasRelatedWork W2261979129 @default.
• W2004281409 hasRelatedWork W2415599293 @default.
• W2004281409 hasRelatedWork W2748952813 @default.
• W2004281409 hasRelatedWork W2809065569 @default.
• W2004281409 hasRelatedWork W2899084033 @default.
• W2004281409 hasRelatedWork W2899790203 @default.
• W2004281409 hasRelatedWork W3116692209 @default.
• W2004281409 hasRelatedWork W4251788210 @default.
• W2004281409 hasRelatedWork W4313304378 @default.
• W2004281409 isParatext "false" @default.
• W2004281409 isRetracted "false" @default.
• W2004281409 magId "2004281409" @default.
• W2004281409 workType "article" @default.